Importance: Autism spectrum disorder (ASD), characterized by deficits in social communication and the presence of restricted, repetitive behaviors or interests, is a neurodevelopmental disorder affecting approximately 2.3% children aged 8 years in the US and approximately 2.2% of adults. This review summarizes evidence on the diagnosis and treatment of ASD.
Observations: The estimated prevalence of ASD has been increasing in the US, from 1.1% in 2008 to 2.3% in 2018, which is likely associated with changes in diagnostic criteria, improved performance of screening and diagnostic tools, and increased public awareness. No biomarkers specific to the diagnosis of ASD have been identified. Common early signs and symptoms of ASD in a child's first 2 years of life include no response to name when called, no or limited use of gestures in communication, and lack of imaginative play. The criterion standard for the diagnosis of ASD is a comprehensive evaluation with a multidisciplinary team of clinicians and is based on semistructured direct observation of the child's behavior and semistructured caregiver interview focused on the individual's development and behaviors using standardized measures, such as the Autism Diagnostic Observation Schedule-Second Edition and the Autism Diagnostic Interview. These diagnostic measures have sensitivity of 91% and 80% and specificity of 76% and 72%, respectively. Compared with people without ASD, individuals with ASD have higher rates of depression (20% vs 7%), anxiety (11% vs 5%), sleep difficulties (13% vs 5%), and epilepsy (21% with co-occurring intellectual disability vs 0.8%). Intensive behavioral interventions, such as the Early Start Denver Model, are beneficial in children 5 years or younger for improvement in language, play, and social communication (small to medium effect size based on standardized mean difference). Pharmacotherapy is indicated for co-occurring psychiatric conditions, such as emotion dysregulation or attention-deficit/hyperactivity disorder. Risperidone and aripiprazole can improve irritability and aggression (standardized mean difference of 1.1, consistent with a large effect size) compared with placebo. Psychostimulants are effective for attention-deficit/hyperactivity disorder (standardized mean difference of 0.6, consistent with a moderate effect size) compared with placebo. These medications are associated with adverse effects including, most commonly, changes in appetite, weight, and sleep.
Conclusions and relevance: ASD affects approximately 2.3% of children aged 8 years and approximately 2.2% of adults in the US. First-line therapy consists of behavioral interventions, while co-occurring psychiatric conditions, such as anxiety or aggression, may be treated with specific behavioral therapy or medication.
Casseus M, Kim WJ, Horton DB. Casseus M, et al. Autism Res. 2023 Apr;16(4):855-867. doi: 10.1002/aur.2894. Epub 2023 Jan 16. Autism Res. 2023. PMID: 36644987 Free PMC article.
Christensen DL, Maenner MJ, Bilder D, Constantino JN, Daniels J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, Pettygrove SD, Robinson C, Shenouda J, White T, Zahorodny W, Pazol K, Dietz P. Christensen DL, et al. MMWR Surveill Summ. 2019 Apr 12;68(2):1-19. doi: 10.15585/mmwr.ss6802a1. MMWR Surveill Summ. 2019. PMID: 30973853 Free PMC article.
Anagnostou E. Anagnostou E. Curr Opin Neurol. 2018 Apr;31(2):119-125. doi: 10.1097/WCO.0000000000000542. Curr Opin Neurol. 2018. PMID: 29389748 Review.
Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, Kurzius-Spencer M, Zahorodny W, Robinson Rosenberg C, White T, Durkin MS, Imm P, Nikolaou L, Yeargin-Allsopp M, Lee LC, Harrington R, Lopez M, Fitzgerald RT, Hewitt A, Pettygrove S, Constantino JN, Vehorn A, Shenouda J, Hall-Lande J, Van Naarden Braun K, Dowling NF. Baio J, et al. MMWR Surveill Summ. 2018 Apr 27;67(6):1-23. doi: 10.15585/mmwr.ss6706a1. MMWR Surveill Summ. 2018. PMID: 29701730 Free PMC article.
Lamy M, Erickson CA. Lamy M, et al. Curr Probl Pediatr Adolesc Health Care. 2018 Oct;48(10):250-264. doi: 10.1016/j.cppeds.2018.08.015. Epub 2018 Sep 24. Curr Probl Pediatr Adolesc Health Care. 2018. PMID: 30262163 Review.
Khan S, Vij K, Lopez E. Khan S, et al. Cureus. 2024 Jul 31;16(7):e65845. doi: 10.7759/cureus.65845. eCollection 2024 Jul. Cureus. 2024. PMID: 39219950 Free PMC article.
Hou Y, Song Z, Deng J, Song X. Hou Y, et al. Front Public Health. 2024 Aug 14;12:1399642. doi: 10.3389/fpubh.2024.1399642. eCollection 2024. Front Public Health. 2024. PMID: 39206007 Free PMC article.
Khan NA, Shang X. Khan NA, et al. Brain Sci. 2024 Jul 29;14(8):766. doi: 10.3390/brainsci14080766. Brain Sci. 2024. PMID: 39199460 Free PMC article.
Gholamalizadeh H, Amiri-Shahri M, Rasouli F, Ansari A, Baradaran Rahimi V, Reza Askari V. Gholamalizadeh H, et al. Brain Sci. 2024 Jul 23;14(8):737. doi: 10.3390/brainsci14080737. Brain Sci. 2024. PMID: 39199432 Free PMC article. Review.
Cano ACSS, Santos D, Beltrão-Braga PCB. Cano ACSS, et al. Adv Neurobiol. 2024;39:269-284. doi: 10.1007/978-3-031-64839-7_11. Adv Neurobiol. 2024. PMID: 39190079 Review.